Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04887831
Title Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab (PRESERVE3)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors G1 Therapeutics, Inc.

transitional cell carcinoma


Cisplatin + Gemcitabine + Trilaciclib

Avelumab + Trilaciclib

Carboplatin + Gemcitabine + Trilaciclib

Avelumab + Cisplatin + Gemcitabine

Avelumab + Carboplatin + Gemcitabine

Age Groups: senior | adult
Covered Countries USA | FRA | ESP

No variant requirements are available.